Type 2 Diabetes Mellitus Treatment Market Research Report: By Treatment (Drug (Insulin, Sensitizers, Sglt-2, Alpha-Glucosidase Inhibitors, Others), Devices (Blood Glucose Monitoring, Insulin Delivery Devices)), By The End User – Forecast Till 2027
ID: MRFR/Pharma/4214-HCR | August 2022 | Region: Global | 85 Pages
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Type 2 diabetes mellitus treatment Market, by treatment
6.1 Introduction
6.2 Drug Class
6.2.1 Market Estimates & Forecast, 2020 – 2027
6.3 Devices
6.3.1 Market Estimates & Forecast, 2020 – 2027
6.4 Others
6.4.1 Market Estimates & Forecast, 2020 – 2027
Chapter 7. Global Type 2 diabetes mellitus treatment Market, by End User
7.1 Introduction
7.2 Hospitals
7.2.1 Market Estimates & Forecast, 2020 – 2027
7.3 Clinics
7.3.1 Market Estimates & Forecast, 2020 – 2027
7.4 Diagnostic Centers
7.4.1 Market Estimates & Forecast, 2020 – 2027
7.5 Drug Stores
7.5.1 Market Estimates & Forecast, 2020 – 2027
7.6 Pharmacies
7.6.1 Market Estimates & Forecast, 2020 – 2027
7.7 Others
7.7.1 Market Estimates & Forecast, 2020 – 2027
Chapter 8. Global Type 2 diabetes mellitus treatment Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 U.S.
8.2.1.1 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 U.K
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Republic of Korea
8.4.6 Rest of Asia Pacific
8.5 The Middle East & Africa
8.5.1 United Arab Emirates
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of the Middle East & Africa
Chapter 9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
9.3.1 Key Developments
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Types Overview
10.1.3 Financials
10.1.4 SWOT Analysis
10.2 AstraZeneca
10.2.1 Company Overview
10.2.2 Types Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Eli Lilly
10.3.1 Company Overview
10.3.2 Types Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Merck
10.4.1 Company Overview
10.4.2 Types/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 BECTON, DICKINSON AND COMPANY
10.5.1 Company Overview
10.5.2 Types Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.6 Sanofi
10.6.1 Company Overview
10.6.2 Types Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.7 BOEHRINGER INGELHEIM
10.7.1 Overview
10.7.2 Types Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Others
Chapter 11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s View Point
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Prediction of Type 2 diabetes mellitus treatment industry
Chapter 12 Appendix
LIST OF TABLES
Table 1 Type 2 diabetes mellitus treatment Industry Synopsis, 2020 – 2027
Table 2 Type 2 diabetes mellitus treatment Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Type 2 diabetes mellitus treatment Market by Region, 2020 – 2027, (USD Million)
Table 4 Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 5 Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027, (USD Million)
Table 6 North America Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 7 North America Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027, (USD Million)
Table 8 US Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 9 US Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027, (USD Million)
Table 10 Canada Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 11 Canada Type 2 diabetes mellitus treatment market by End Users, 2020 – 2027, (USD Million)
Table 12 South America Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 13 South America Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027, (USD Million)
Table 14 Europe Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 15 Europe Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027, (USD Million)
Table 16 Western Europe Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 17 Western Europe Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027, (USD Million)
Table 18 Eastern Europe Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 19 Eastern Europe Type 2 diabetes mellitus treatment Market by End Users, 2020 – 2027, (USD Million)
Table 20 Asia Pacific Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 21 Asia Pacific Type 2 diabetes mellitus treatment market by End Users, 2020 – 2027, (USD Million)
Table 22 The Middle East & Africa Type 2 diabetes mellitus treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 23 The Middle East & Africa Type 2 diabetes mellitus treatment market by End Users, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Type 2 diabetes mellitus treatment Market
Figure 3 Segmentation Market Dynamics for Type 2 diabetes mellitus treatment Market
Figure 4 Global Type 2 diabetes mellitus treatment market Share, by Treatment 2020
Figure 5 Global Type 2 diabetes mellitus treatment market Share, by End Users, 2020
Figure 6 Global Type 2 diabetes mellitus treatment market Share, by Region, 2020
Figure 7 North America Type 2 diabetes mellitus treatment market Share, by Country, 2020
Figure 8 Europe Type 2 diabetes mellitus treatment market Share, by Country, 2020
Figure 9 Asia Pacific Type 2 diabetes mellitus treatment market Share, by Country, 2020
Figure 10 Middle East & Africa Type 2 diabetes mellitus treatment market Share, by Country, 2020
Figure 11 Global Type 2 diabetes mellitus treatment market: Company Share Analysis, 2020 (%)
Figure 12 Abbott Laboratories: Key Financials
Figure 13 Abbott Laboratories: Segmental Revenue
Figure 14 Abbott Laboratories: Geographical Revenue
Figure 15 AstraZeneca: Key Financials
Figure 16 AstraZeneca: Segmental Revenue
Figure 17 AstraZeneca: Geographical Revenue
Figure 18 Eli Lilly: Key Financials
Figure 19 Eli Lilly: Segmental Revenue
Figure 20 Eli Lilly: Geographical Revenue
Figure 21 Merck: Key Financials
Figure 22 Merck: Segmental Revenue
Figure 23 Merck: Geographical Revenue
Figure 24 BECTON, DICKINSON AND COMPANY: Key Financials
Figure 25 BECTON, DICKINSON AND COMPANY: Segmental Revenue
Figure 26 BECTON, DICKINSON AND COMPANY Geographical Revenue
Figure 27 Sanofi: Key Financials
Figure 28 Sanofi: Segmental Revenue
Figure 29 Sanofi: Geographical Revenue
Figure 30 BOEHRINGER INGELHEIM: Key Financials
Figure 31 BOEHRINGER INGELHEIM: Segmental Revenue
Figure 32 BOEHRINGER INGELHEIM: Geographical Revenue
Speak to Analyst
Request a Free Sample
Type 2 Diabetes Mellitus Treatment Market Scenario:
It is estimated that the type 2 diabetes mellitus treatment market is expected to grow at a CAGR 8.0% during the forecast period of 2017-2023. Type 2 diabetes mellitus is a metabolic disorder which results from an excess of caloric intake over energy expenditure. The condition is characterized by progressive insulin secretory defect, which increases the body’s demand for insulin in order to retain glucose homeostasis. Hyperglycemia is a major symptom of type 2 diabetes mellitus. According to the National Diabetes Statistics Report suggested by CDC, it is found that 9.4% of the U.S. population, i.e. 30.3 million people had diabetes in 2015.
It is noted that rising technological advancements and escalating prevalence are the key factors driving the type 2 diabetes mellitus treatment market. With the rising awareness about the condition, market players are coming up with novel drugs and devices owing to technological advancements. For instance, in December 2017, Novo Nordisk received FDA approval for Ozempic (semaglutide). The drug was specially designed for the treatment of type 2 diabetes mellitus. In the same year, Merck has also received FDA approval for Steglatro (ertugliflozin).
Various other factors such as growing awareness, huge research funding in diabetes diagnosis and treatment, unmet medical needs, increasing global prevalence of obesity, improving regulatory framework, increasing government assistance, and increasing adoption rate, are continuously contributing to the growth of the global type 2 diabetes mellitus treatment market.
Despite these drivers, there are some issues associated with type 2 diabetes mellitus treatment market. The high cost associated with diagnosis and treatment of diabetes, side effects of available treatment options, and poor healthcare system in low and middle-income countries may hamper the growth of the market to an extent.
Segmentation
The global type 2 diabetes mellitus treatment market is segmented on the basis of treatment and end user.
On the basis of the treatment, the market is classified as a drug class and devices. The drug class is further segmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs, others. The sub-segment of sensitizers includes thiazolidinediones and biguanides. The sub-segment of secretagogues includes sulfonylureas and non-sulfonylureas. The devices market is further segmented into blood glucose monitoring devices and insulin delivery devices. The sub-segment of blood glucose monitoring devices includes testing strips, lancets, continuous glucose monitors, self-monitoring blood glucose meters, and others. The sub-segment of insulin delivery devices includes insulin pens, insulin pumps, insulin syringes, and insulin jet injectors.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the type 2 diabetes mellitus treatment market owing to the presence of patient population, a well-developed technology, high healthcare expenditure, and the presence of the leading players. Due to the rising prevalence of diabetes, various companies, and government associations are actively participating in improving diabetes care. For instance, The Merck Foundation has provided funding of around USD 10,000,000 for the projects designed to improve diabetes care in the United States.
Europe holds the second position in the type 2 diabetes mellitus treatment market. It is expected that the government support towards research & development expenditure and amendments in reimbursement policies in the healthcare is likely to drive the European market. As per the German maternity guidelines, every pregnant woman can undergo glucose challenge test for the early diagnosis of Gestational diabetes mellitus, and the charges for the test are completely covered by women’s health insurance.
Asia Pacific is the fastest growing type 2 diabetes mellitus treatment market owing to a huge patient pool, increasing demand, and development in healthcare technology.
The Middle East & Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.
Key Players
Some of key the players in the global type 2 diabetes mellitus treatment market are Abbott Laboratories, Acon Laboratories, Inc., Adocia, Akros Pharma, Amgen, AstraZeneca, Bayer AG, Becton, Dickinson and Company, Biocon, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Novartis & Co., Novo Nordisk, Peptron, Pfizer, Roche Diagnostics Ltd., Sanofi, Sunpharma, Takeda Pharmaceuticals, and others.
Intended Audience
- Pharmaceutical Companies
- Medical Device Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: Significant Value |
| CAGR | 8.0% (2017-2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment, Devices and End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Abbott Laboratories, Acon Laboratories, Inc., Adocia, Akros Pharma, Amgen, AstraZeneca, Bayer AG, Becton, Dickinson and Company, Biocon, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Novartis & Co., Novo Nordisk, Peptron, Pfizer, Roche Diagnostics Ltd., Sanofi, Sunpharma, Takeda Pharmaceuticals |
| Key Market Opportunities | Growing awareness and huge research funding in diabetes diagnosis and treatment |
| Key Market Drivers | Rising technological advancements and escalating prevalence |
